C$0.76 AIDX.TO Healwell AI Inc. TSX 30 Mar 2026: AI pivot shapes short-term outlook

AIDX.TO stock trades at C$0.76 intraday on 30 Mar 2026, down 2.56% for the session as volume runs light at 51,059 shares on the TSX. Investors tracking Healwell AI Inc. (AIDX.TO) should note the company’s AI-first healthcare positioning, recent margin pressures and an upcoming earnings date on 13 May 2026. This piece gives a clear intraday snapshot, concise fundamental metrics and a model-based forecast to frame short-term moves and risk.

AIDX.TO stock intraday price and volume

Healwell AI Inc. (AIDX.TO) is trading C$0.76 on the TSX with a day low of C$0.74 and day high of C$0.77. Volume is 51,059 versus an average of 552,374, signalling below-average intraday activity. The stock is down C$0.02 today, or -2.56%, which aligns with a weak sector session in Canadian healthcare.

AIDX.TO stock fundamentals and financials

On fundamentals, AIDX.TO shows a trailing EPS of -0.15 and a negative P/E of -5.20, reflecting ongoing losses. Market cap sits near C$228.79M with 293,322,517 shares outstanding. Key ratios: price-to-sales 1.95, price-to-book 1.83, current ratio 0.91, and debt-to-equity 0.69. Gross margin is healthy at 45.38%, but operating margin is -27.22%, highlighting that revenue quality exists while profitability remains negative.

AIDX.TO stock technicals and trading signals

Technical indicators show mixed short-term momentum: RSI 44.25 and MACD histogram -0.02. Bollinger Bands middle sits at C$0.86 with a lower band at C$0.72, suggesting current price is near lower band support. ATR is C$0.06, and CCI at -141.06 flags short-term oversold conditions. Traders should respect low average daily liquidity when sizing positions.

AIDX.TO stock Meyka grade and analyst view

Meyka AI rates AIDX.TO with a score out of 100 at 61.58 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Note external company rating (dated 27 Mar 2026) showed a C- and a strong sell signal on some DCF metrics, underlining divergent model views. These grades are not guaranteed and we are not financial advisors.

AIDX.TO stock forecast and price targets

Meyka AI’s forecast model projects monthly C$0.65, quarterly C$0.72, and yearly C$0.40. Versus the current C$0.76, the quarterly projection implies an implied near-term downside of -5.26%, monthly downside -14.47%, and 12-month downside -47.44%. There is no consensus broker price target published. Given mixed fundamentals and low liquidity, scenario targets are more useful than a single point estimate.

AIDX.TO stock risks and opportunities

Primary risks: continued negative operating cash flow (OCF per share -0.07), interest coverage -3.09, and thin trading volumes that magnify price moves. Opportunities include Healwell’s AI decision-support focus and its strategic alliance with WELL Health Technologies, which could lift recurring revenue if adoption accelerates. Investors should weigh growth-readiness against capital and execution risk.

Final Thoughts

Key takeaways for AIDX.TO stock: the intraday price of C$0.76 on 30 Mar 2026 reflects thin volume and mixed signals between revenue quality and negative profitability. Meyka AI’s model projects a near-term quarterly level of C$0.72 and a 12-month model target of C$0.40, implying downside from the current price. Our Meyka grade (B, score 61.58 of 100) labels the stock a HOLD on the balance of growth potential and execution risk. Given an EPS of -0.15, price-to-sales 1.95, and a current ratio below 1.00, investors seeking exposure to AI healthcare should size positions carefully and monitor the earnings release on 13 May 2026. For more company detail visit the Healwell site Healwell AI and our intraday hub at Meyka stock page. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.